OrsoBio

Executive Summary

OrsoBio is a clinical-stage biopharmaceutical company developing first-in-class therapies for severe metabolic disorders, including obesity, diabetes, dyslipidemias, and MASH. Founded in 2020 and headquartered in Palo Alto, California, the company targets fundamental energy metabolism pathways to address root causes of these diseases. While OrsoBio remains private and has not disclosed specific pipeline details, its focus on novel mechanisms positions it within a high-demand therapeutic area with significant unmet need. The company's progress will depend on successful execution of early-stage clinical trials and potential partnerships to advance its candidates.

Upcoming Catalysts (preview)

• Q2 2027Phase 1/2 data readout for lead metabolic program40% success
• Q4 2026Series B or later financing round70% success
• TBDPotential licensing or collaboration deal50% success